Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2678

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2678
---

bylaws and the indemnification agreements that we entered into with our directors and officers provide that:

    ●
    we
    will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at its request,
    to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant
    and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;

    ●
    we
    may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;

    ●
    we
    are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that
    such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled
    to indemnification;

127

    ●
    we
    are be obligated by our organizational documents to indemnify a person with respect to proceedings initiated by that person against
    us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right
    to indemnification; and

    ●
    the
    rights conferred in the Amended Certificate and the Company’s bylaws are not exclusive, and we are authorized to enter into
    indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.

If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.

The
trading market for our common stock and warrants is influenced by the research and reports that industry or securities analysts may publish
about us, our business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on
us. If no securities or industry analysts commence coverage of us, our share price and trading volume would likely be negatively impacted.
If any of the analysts who may cover us change their recommendation regarding our common stock or warrants adversely or provide more
favorable relative recommendations about our competitors, the price of shares of our common stock and warrants would likely decline.
If any analyst who may cover us